Big comeback? The Q1 report on biotech is in, and there’s been some sputtering
DealForma’s Chris Dokomajilar has been running the numbers again and backs up some of the things we were already pretty sure about — while raising new questions about just how deep and lasting this biotech recovery can be. At the top of the list of Q1 trends: PIPEs are brimming, follow-ons